NCT03666026 is a NA clinical trial of 1 MyChart R/R in Influenza, sponsored by University of California, Los Angeles.

Who is sponsoring NCT03666026?

NCT03666026 is sponsored by University of California, Los Angeles.

What drugs are being tested in NCT03666026?

Interventions in NCT03666026: 1 MyChart R/R, 2 MyChart R/R, 3 MyChart R/R.

What condition does NCT03666026 study?

NCT03666026 studies Influenza, Respiratory Tract Infections, Vaccines.

Is NCT03666026 still recruiting?

NCT03666026 is currently completed. Last updated 17 November 2021.

Are results published for NCT03666026?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-11-17 · How we verify

NCT03666026

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Patient Portal - Flu Reminder Recall

Completed NA Results posted Last updated 17 November 2021

What this trial tests

NA trial testing 1 MyChart R/R in Influenza in 164,205 participants. Completed in 2 April 2019.

Timeline

2 October 2018

Primary endpoint
2 April 2019

2 April 2019

Quick facts

Lead sponsor	University of California, Los Angeles
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	health services research
Enrollment	164,205
Start date	2 October 2018
Primary completion	2 April 2019
Estimated completion	2 April 2019
Sites	1 location across United States

Drugs / interventions tested

1 MyChart R/R
2 MyChart R/R
3 MyChart R/R

Conditions studied

Influenza — all drugs for Influenza →
Respiratory Tract Infections — all drugs for Respiratory Tract Infections →
Vaccines — all drugs for Vaccines →

Sponsor

University of California, Los Angeles

Who can join

4 Months and older, any sex, with Influenza or Respiratory Tract Infections. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

1.Receipt of the Annual Influenza Vaccine (Between 10/1/18 - 4/2/19) Among Index Patients. Outcomes Will be Assessed Via Vaccine Data Extraction From the Electronic Health Record and External Claims and Pharmacy Data. Primary · October 1, 2018 to April 2, 2019 during influenza vaccination season

Number of participants in each arm who received influenza vaccination

Group	Value	95% CI
Standard of Care Control	15385
1 MyChart R/R	15604
2 MyChart R/R	15660
3 MyChart R/R	15673

Sponsor's own description

This trial is taking place in Los Angeles, CA at clinics within the UCLA Health System. Despite the Advisory Committee on Immunization Practices (ACIP) recommendation in 2010 that all people above 6 months of age should receive an annual flu vaccine, vaccination rates remain low: at 6m-4.9 yrs. (70%), 5-17.9 yrs. (56%), 18-64.9 yrs. (38%), and \>65 yrs. (63%). The investigators will assess the effectiveness and cost-effectiveness of 1, 2, 3 MyChart R/R messages as compared to the standard of care control (no messages).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of Patient Portal Reminders Sent by a Health Care System on Influenza Vaccination Rates: A Randomized Clinical Trial.
Szilagyi PG, Albertin C, Casillas A, Valderrama R, et al · · 2020 · cited 59× · PMID 32421168 · DOI 10.1001/jamainternmed.2020.1602

Verify or expand the search:

Other recruiting trials for Influenza

Currently open trials in the same condition.

NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
NCT07302256 — A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 1 · recruiting
NCT07431840 — Immune Defense Protein Impact On Respiratory Immune Outcomes · NA · recruiting
NCT07485855 — Influenza Vaccination Strategy for Patients With Hematologic Malignancy · Phase 3 · recruiting

Other University of California, Los Angeles trials

Trials by the same sponsor.

NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03666026 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
Last refreshed: 17 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03666026.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing